Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13, 2024 16:01 ET
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
May 09, 2024 08:30 ET
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
May 08, 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
SkinCure Oncology’s GentleCure™ Experience to be Featured in National Public Health PSA Series
May 08, 2024 09:00 ET
|
SkinCure Oncology LLC
GentleCure will be recognized as an innovative healthcare technology in an upcoming public service announcement (PSA) about nonmelanoma skin cancer.
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
May 07, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
May 06, 2024 08:00 ET
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
May 02, 2024 07:33 ET
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Dermatology Collaboration and...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
May 01, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...